Physician profile
Edward George
NPI 1407851256
$322,658.66
in general payments reported to CMS, 2019-2025
34 companies · $2,246 in 2025
The $2,246 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182K · 2020: $51K · 2021: $62K · 2022: $21K · 2023: $3,317 · 2024: $2,101 · 2025: $2,246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $3,450 · Consulting Fee: $2,923 · Food and Beverage: $1,292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $3,450.00 |
| Consulting Fee | $2,922.50 |
| Food and Beverage | $1,291.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $132,825.95 | 2019-2023 | Ultomiris |
| Amgen INC. | $75,873.18 | 2019-2020 | |
| Rigel Pharmaceuticals, INC. | $35,511.14 | 2019-2022 | |
| Genzyme Corporation | $31,959.31 | 2019-2024 | |
| Eusa Pharma (US) LLC | $21,384.21 | 2020-2021 | |
| Array Biopharma INC | $5,618.77 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $3,662.27 | 2024-2025 | |
| Abbvie INC. | $3,143.45 | 2023-2025 | |
| Celgene Corporation | $1,695.00 | 2020 | |
| Glaxosmithkline, LLC. | $1,625.00 | 2022 | |
| Karyopharm Therapeutics INC. | $1,550.00 | 2021 | |
| G1 Therapeutics, INC. | $1,500.00 | 2022 | |
| Gilead Sciences, INC. | $1,011.92 | 2021 | |
| Immunomedics, INC. | $1,000.00 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $560.37 | 2019-2024 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $458.84 | 2019-2024 | Jakafi, Monjuvi |
| Dova Pharmaceuticals | $360.75 | 2019-2020 | |
| Athenex Pharmaceutical Division, LLC | $350.00 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $339.74 | 2019-2020 | |
| Seagen INC. | $249.14 | 2019 | |
| Merck Sharp & Dohme LLC | $241.09 | 2019-2024 | Keytruda |
| Genentech USA, INC. | $239.03 | 2019 | |
| Astellas Pharma US INC | $222.43 | 2019 | |
| Novocure Gmbh | $200.00 | 2022 | |
| Kite Pharma, INC. | $196.72 | 2022-2023 | Yescarta |
| Taiho Oncology, INC. | $124.93 | 2022 | |
| Emd Serono, INC. | $120.15 | 2024 | |
| Pharmaessentia USA Corporation | $120.04 | 2022 | |
| Adaptive Biotechnologies Corporation | $101.89 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $94.41 | 2019 | |
| Stemline Therapeutics INC. | $86.97 | 2023 | Orserdu |
| E.R. Squibb & Sons, L.L.C. | $86.65 | 2019 | |
| Lilly USA, LLC | $84.00 | 2019 | |
| Allergan, INC. | $61.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.